BBHC
BMY.RT

Brown Brothers Harriman & Co’s Bristol-Myers Squibb Company Contingent Value Rights BMY.RT Stock Holding History

Brown Brothers Harriman & Co’s Portfolio BMY.RT Stock Details BMY.RT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q1 		– Sell
-5,838
Closed -$4K – 1288
2020
Q4 		$4K Buy
5,838
+400
+7% +$852 ﹤0.01% 979
2020
Q3 		$12K Sell
5,438
-834
-13% -$2.38K ﹤0.01% 748
2020
Q2 		$22K Sell
6,272
-4,508
-42% -$16.3K ﹤0.01% 678
2020
Q1 		$41K Sell
10,780
-2,832
-21% -$9.33K ﹤0.01% 554
2019
Q4 		$41K Buy
+13,612
New +$35.4K ﹤0.01% 703

Other funds holding BMY.RT

JCI
Jet Capital Investors New York $51M AUM 48.01% 1-Year Est. Return
Tudor Investment Corp
Tudor Investment Corp Stamford, Connecticut $53.9B AUM 29.12% 1-Year Est. Return
BC
Brookfield Corp Toronto, Ontario, Canada $74.2B AUM 0.68% 1-Year Est. Return
TNB
Thomasville National Bank Thomasville, Georgia $1.82B AUM
WAM
Westport Asset Management Southport, Connecticut $226M AUM 16.76% 1-Year Est. Return
IAIM
International Assets Investment Management Orlando, Florida $1.67B AUM 28.26% 1-Year Est. Return

Brown Brothers Harriman & Co's BMY.RT Position: Q1 2021 in Review

Brown Brothers Harriman & Co sold out of Bristol-Myers Squibb Company Contingent Value Rights (BMY.RT) in Q1 2021, closing a stake of 5,838 shares — an estimated $4K sold.

Brown Brothers Harriman & Co first reported a position in BMY.RT in Q4 2019 and held it in 5 quarters. The position peaked at $41K in Q1 2020. 12 funds tracked by Wall St. Rank hold BMY.RT as of Q1 2021.

  • Brown Brothers Harriman & Co reported no remaining Bristol-Myers Squibb Company Contingent Value Rights position as of Q1 2021 after selling out during the quarter.
  • Brown Brothers Harriman & Co sold 5,838 Bristol-Myers Squibb Company Contingent Value Rights shares in Q1 2021, an estimated $4K.
  • Brown Brothers Harriman & Co first reported a position in Bristol-Myers Squibb Company Contingent Value Rights in Q4 2019 and held it in 5 quarters.
  • Brown Brothers Harriman & Co's Bristol-Myers Squibb Company Contingent Value Rights position peaked at $41K in Q1 2020.
  • 12 funds tracked by Wall St. Rank held Bristol-Myers Squibb Company Contingent Value Rights as of Q1 2021.

Based on Brown Brothers Harriman & Co's 13F filing for Q1 2021, filed 13 May 2021.